Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03927833

Cycled Phototherapy

Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (< 750 g BW or <27 weeks GA).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Hyper Bilirubinemia Congenital, Hereditary, and Neonatal Diseases and Abnormalities Female Urogenital Diseases and Pregnancy Complications Infant, Newborn, Diseases Obstetric Labor Complications Obstetric Labor, Premature Pregnancy Complications Premature Birth Premature Infant Urogenital Diseases

Age range

22 week–27 week

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama at Birmingham, Birmingham, Alabama, United States

Loading trial locations.

About this study

Were they not delivered early, extremely premature infants would normally develop in darkness within the uterus for 3-4 more months longer before birth. Yet, the routine care of these infants has involved the use of uninterrupted (continuous) exposure to bright light during phototherapy (PT), a treatment method that neonatologists have assumed has no serious adverse effects on even the most immature of newborns.

Immaturity, thin translucent skin, and a multitude of other problems may make extremely premature infants highly vulnerable to the photo-oxidative injury, lipid peroxidation, DNA damage, reduced cerebral and mesenteric blood flow, or other serious potential hazards of uninterrupted exposure to PT that have now been identified. Such hazards were not recognized when continuous PT was widely incorporated into neonatal care, and the survival rate of extremely premature infants (<27 wks gestation or <750 g birth weight) was much lower than today.

PT rapidly photoisomerizes bilirubin in the subcutaneous tissues and vasculature, and six trials of cycled PT have demonstrated that use of cycled PT reduces the total hours of PT and results in minimal or no increase in peak TSB over that with continuous PT in term or moderately preterm infants. Recent findings from a pilot study (NCT01944696) support a PT regimen for this Cycled Phototherapy protocol.

Infants born at one of the Neonatal Research Network centers, ≤ 750 grams at birth and/or < 27 weeks gestation at birth by best OB estimate will be considered for this study.

Those who qualify will be randomized to either cycled PT or continuous PT. The cycled phototherapy begins with >15 min/h cycled PT regimen and increased to 30 min/h if the TSB is 8.0-9.9 and 60 min/h if the TSB is >10 mg/dL. Those randomized to continuous phototherapy will undergo continuous exposure,as that is commonly used in NRN centers.

The PT lamp position will be adjusted to meet the irradiance (µW/cm2/nm) goal of 22 at the umbilicus. The irradiance goal in both groups will be increased from 22 to 33 at a TSB of 10-13 and to 40 at a TSB >13.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants is inborn
  • Infant is ≤ 750 grams at birth and/or < 27 weeks gestation at birth by best OB estimate
  • Infant is 12-36 hours of age.

Exclusion criteria

  • Unable to enroll infant by 36 hours of age
  • Previous phototherapy
  • Known hemolytic disease
  • TSB reported as >6.0 mg/dL before 12 hours age
  • Major anomaly
  • Overt nonbacterial infection
  • Infant is likely to expire soon: Limiting or withdrawal of intensive care is being recommended to the parents, the parents are requesting withdrawal of care, or the pH is < 6.80 or persistent bradycardia with hypoxemia for >2h.

Treatment and study plan

Phototherapy lights

Device

Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.

Primary outcomes

  1. Number of participants survival to discharge

    Time frame: Birth to hospital discharge, up to 120 days of life

    Number of Participants discharged from hospital alive, after birth.

Secondary outcomes

  1. Number of hours of Phototherapy

    Time frame: Start until the end of intervention period (duration of 2 weeks)

    The reported values will be the mean total hours of phototherapy during the two week intervention period.

  2. Number of irradiance hours

    Time frame: Start until the end of intervention period (duration of 2 weeks)

    The reported values will be the mean total hours of irradiance during the two week intervention period.

  3. Peak Concentration of Total Serum Bilirubin

    Time frame: Start until the end of intervention period (duration of 2 weeks)

    The reported values will be the mean peak total serum bilirubin (mg/dL) during the two week intervention period.

  4. Concentration of Total Serum Bilirubin

    Time frame: Start until the end of intervention period (duration of 2 weeks)

    The reported values will be the mean total serum bilirubin (mg/dL) during the two week intervention period.

  5. Number of Participants with Major neonatal morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    Major neonatal morbidity is defined as a severe ICH, ventricular enlargement of cystic white matter disease, BPD, late onset sepsis, NEC or spontaneous intestinal perforation, or >grade 3 ROP before discharge.

  6. Number of Participants with Severe ICH, as a component of the predischarge morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    As recorded for the sonongram with the most severe finding in the blood/echodensity in the ventricle or blood/echodensity in the parenchyma

  7. Number of Participants with Ventricular enlargement of cystic white matter disease, as a component predischarge morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    If a MRI was done: ventricular size enlarged, cystic PVL or porencephalic /posthemorrhagic cyst/multicystic encephalomalacia observed. If a MRI was not done: the same items as above for sonograms after day 28.

  8. Number of Participants with Bronchopulmonary dysplasia (BPD), as a component predischarge morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    BPD defined as highest FiO2 at 36 wk: >0.21

  9. Number of Participants with Late onset sepsis, as a component predischarge morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    Late onset blood culture positive septicemia/bacteremia at >72 hours of age.

  10. Number of Participants with Necrotising enterocolitis (NEC) or spontaneous intestinal perforation, as a component predischarge morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    Either proven NEC or spontaneous gastrointestinal perforation without proven NEC.

  11. Number of Participants with Grade 3 (or greater) retinopathy of prematurity (ROP), as a component predischarge morbidity

    Time frame: Birth to hospital discharge, up to 120 days of life

    Stage 3 ROP observed in either eye.

  12. Number of Participants with Patent ductus arteriosus (PDA) treated with surgery or NSAIDS

    Time frame: Birth to hospital discharge, up to 120 days of life

    PDA treated with surgery or NSAIDS (indomethacin, ibuprofen or acetaminophen)

  13. Number of Participants with Neurodevelopmental Impairment

    Time frame: Birth to 26 months corrected age

    Neurodevelopmental Impairment (NDI), as assessed in a sub-population of follow-up of infants <27 wks gestation. Severe NDI will be defined by any of the following: a BSID III cognitive score < 70, Gross Motor Functional (GMF) Level of 3-5, blindness (<20/200 vision) or profound hearing loss (inability to understand commands despite amplification); moderate NDI will be defined as a BSID III cognitive score 70-84 and either a GMF level of 2 or a hearing deficit requiring amplification to understand commands or unilateral blindness; mild NDI will be defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMF level 1 or hearing loss not requiring amplification. Normal (no NDI) will be defined by a cognitive score ≥ 85 and absence of any neurosensory deficits.

  14. Number of Participants with Neurodevelopmental Impairment or Death

    Time frame: Birth to 26 months corrected age

    NDI defined in outcome #9

Sponsors and collaborators

Lead sponsor

NICHD Neonatal Research Network

Network

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Official study title

Cycled Phototherapy: A Safer Effective Method to Control the Serum Bilirubin Of Extremely Premature Infants?

Important dates

Study start
2020
Primary completion
2025
Study completion
2027
First posted
Apr 25, 2019
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.